These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

146 related articles for article (PubMed ID: 21857110)

  • 1. Synergistic growth inhibition of cancer cells harboring the RET/PTC1 oncogene by staurosporine and rotenone involves enhanced cell death.
    Goncalves AP; Videira A; Maximo V; Soares P
    J Biosci; 2011 Sep; 36(4):639-48. PubMed ID: 21857110
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Effects of silencing RET/PTC1 junction oncogene in human papillary thyroid carcinoma cells.
    Gilbert-Sirieix M; Ripoche H; Malvy C; Massaad-Massade L
    Thyroid; 2010 Oct; 20(10):1053-65. PubMed ID: 20615140
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Activation of the RAS/RAF/ERK signaling pathway contributes to resistance to sunitinib in thyroid carcinoma cell lines.
    Piscazzi A; Costantino E; Maddalena F; Natalicchio MI; Gerardi AM; Antonetti R; Cignarelli M; Landriscina M
    J Clin Endocrinol Metab; 2012 Jun; 97(6):E898-906. PubMed ID: 22442268
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Creation and characterization of a doxycycline-inducible mouse model of thyroid-targeted RET/PTC1 oncogene and luciferase reporter gene coexpression.
    Knostman KA; Venkateswaran A; Zimmerman B; Capen CC; Jhiang SM
    Thyroid; 2007 Dec; 17(12):1181-8. PubMed ID: 18004977
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effects of silencing the RET/PTC1 oncogene in papillary thyroid carcinoma by siRNA-squalene nanoparticles with and without fusogenic companion GALA-cholesterol.
    Ali HM; Maksimenko A; Urbinati G; Chapuis H; Raouane M; Desmaële D; Yasuhiro H; Harashima H; Couvreur P; Massaad-Massade L
    Thyroid; 2014 Feb; 24(2):327-38. PubMed ID: 23885719
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Differential responses of human papillary thyroid cancer cell lines carrying the RET/PTC1 rearrangement or a BRAF mutation to MEK1/2 inhibitors.
    Henderson YC; Fredrick MJ; Clayman GL
    Arch Otolaryngol Head Neck Surg; 2007 Aug; 133(8):810-5. PubMed ID: 17709622
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Role of H2O2 in RET/PTC1 chromosomal rearrangement produced by ionizing radiation in human thyroid cells.
    Ameziane-El-Hassani R; Boufraqech M; Lagente-Chevallier O; Weyemi U; Talbot M; Métivier D; Courtin F; Bidart JM; El Mzibri M; Schlumberger M; Dupuy C
    Cancer Res; 2010 May; 70(10):4123-32. PubMed ID: 20424115
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Ccdc6 knock-in mice develop thyroid hyperplasia associated to an enhanced CREB1 activity.
    Leone V; Langella C; Esposito F; Arra C; Palma G; Rea D; Paciello O; Merolla F; De Biase D; Papparella S; Celetti A; Fusco A
    Oncotarget; 2015 Jun; 6(17):15628-38. PubMed ID: 25970781
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Involvement of p53 in cell death following cell cycle arrest and mitotic catastrophe induced by rotenone.
    Gonçalves AP; Máximo V; Lima J; Singh KK; Soares P; Videira A
    Biochim Biophys Acta; 2011 Mar; 1813(3):492-9. PubMed ID: 21223980
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Sorafenib potently inhibits papillary thyroid carcinomas harboring RET/PTC1 rearrangement.
    Henderson YC; Ahn SH; Kang Y; Clayman GL
    Clin Cancer Res; 2008 Aug; 14(15):4908-4914. PubMed ID: 18676765
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A novel RET/PTC variant detected in a pediatric patient with papillary thyroid cancer without ionization history.
    Halkova T; Dvorakova S; Vaclavikova E; Sykorova V; Vcelak J; Sykorova P; Vlcek P; Reboun M; Katra R; Kodetova D; Schrumpf M; van Wezel T; Morreau H; Bendlova B
    Hum Pathol; 2015 Dec; 46(12):1962-9. PubMed ID: 26472164
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Orthovanadate-induced cell death in RET/PTC1-harboring cancer cells involves the activation of caspases and altered signaling through PI3K/Akt/mTOR.
    Gonçalves AP; Videira A; Soares P; Máximo V
    Life Sci; 2011 Sep; 89(11-12):371-7. PubMed ID: 21807000
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Iodide- and glucose-handling gene expression regulated by sorafenib or cabozantinib in papillary thyroid cancer.
    Ruan M; Liu M; Dong Q; Chen L
    J Clin Endocrinol Metab; 2015 May; 100(5):1771-9. PubMed ID: 25768669
    [TBL] [Abstract][Full Text] [Related]  

  • 14. BRAFV600E and RET/PTC Promote Proliferation and Migration of Papillary Thyroid Carcinoma Cells In Vitro by Regulating Nuclear Factor-κB.
    Zhou D; Li Z; Bai X
    Med Sci Monit; 2017 Nov; 23():5321-5329. PubMed ID: 29117154
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Influence of RET/PTC1 and RET/PTC3 oncoproteins in radiation-induced papillary thyroid carcinomas on amounts of cytoskeletal protein species.
    Zeindl-Eberhart E; Liebmann S; Jungblut PR; Mattow J; Schmid M; Kerler R; Rabes HM
    Amino Acids; 2011 Jul; 41(2):415-25. PubMed ID: 20839015
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Dose-Response Dependences for Frequency of RET/PTC Gene Rearrangements in Papillary Thyroid Carcinoma after Irradiation. Simple Pooling Analysis of Molecular Epidemiological Data].
    Koterov AN; Ushenkova LN; Biryukov AP
    Radiats Biol Radioecol; 2016; 56(1):5-25. PubMed ID: 27245001
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Diffuse sclerosing variant of papillary thyroid carcinoma: major genetic alterations and prognostic implications.
    Joung JY; Kim TH; Jeong DJ; Park SM; Cho YY; Jang HW; Jung YY; Oh YL; Yim HS; Kim YL; Chung JH; Ki CS; Kim SW
    Histopathology; 2016 Jul; 69(1):45-53. PubMed ID: 26568156
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Assessment of RET/PTC oncogene activation and clonality in thyroid nodules with incomplete morphological evidence of papillary carcinoma: a search for the early precursors of papillary cancer.
    Fusco A; Chiappetta G; Hui P; Garcia-Rostan G; Golden L; Kinder BK; Dillon DA; Giuliano A; Cirafici AM; Santoro M; Rosai J; Tallini G
    Am J Pathol; 2002 Jun; 160(6):2157-67. PubMed ID: 12057919
    [TBL] [Abstract][Full Text] [Related]  

  • 19. High iodine concentration attenuates RET/PTC3 oncogene activation in thyroid follicular cells.
    Fiore AP; Fuziwara CS; Kimura ET
    Thyroid; 2009 Nov; 19(11):1249-56. PubMed ID: 19725779
    [TBL] [Abstract][Full Text] [Related]  

  • 20. MEK inhibitor PD0325901 significantly reduces the growth of papillary thyroid carcinoma cells in vitro and in vivo.
    Henderson YC; Chen Y; Frederick MJ; Lai SY; Clayman GL
    Mol Cancer Ther; 2010 Jul; 9(7):1968-76. PubMed ID: 20587665
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.